A 42-year-old man with a history of chronic pancreatitis presents with acute upper GI bleeding from esophageal varices. In addition to variceal band ligation, the physician initiates pharmacotherapy targeting the hormone marked **D** in the diagram. Which of the following best explains the mechanism by which this drug reduces bleeding risk in this clinical scenario?

Explanation

## Why option 1 is correct The hormone marked **D** is somatostatin, a universal inhibitory GI hormone secreted by D cells. Octreotide, a long-acting synthetic somatostatin analog, is the standard pharmacological agent used acutely in esophageal variceal bleeding. Somatostatin and its analogs reduce splanchnic blood flow and portal venous pressure by causing splanchnic vasoconstriction, thereby decreasing the transmural pressure gradient across varices and reducing the risk of rupture and rebleeding. This is the primary mechanism of hemostatic benefit in variceal hemorrhage (Guyton & Hall 14e Ch 65; Harrison 21e Ch 81). ## Why each distractor is wrong - **Option 2**: Somatostatin INHIBITS gastric acid secretion; it does not increase it. Moreover, increased acid would not promote hemostasis at a bleeding varix. This reverses the known action of somatostatin. - **Option 3**: Somatostatin reduces, not enhances, splanchnic blood flow and mucosal perfusion. The therapeutic benefit comes from reduced, not increased, blood flow to the portal system. - **Option 4**: Somatostatin inhibits glucagon secretion (not stimulates it), and enhanced glucagon would worsen portal hypertension by increasing splanchnic vasodilation. This option confuses somatostatin's inhibitory role. **High-Yield:** Octreotide (somatostatin analog) is first-line pharmacotherapy for acute esophageal variceal bleeding because it reduces portal pressure via splanchnic vasoconstriction—not by promoting local hemostasis. [cite: Guyton & Hall 14e Ch 65; Harrison 21e Ch 81]